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Abstract
Motivation: Gene prioritization at human GWAS loci is challenging due to linkage-disequilibrium and long-range
gene regulatory mechanisms. However, identifying the causal gene is crucial to enable identification of potential
drug targets and better understanding of molecular mechanisms. Mapping GWAS traits to known phenotypically
relevant Mendelian disease genes near a locus is a promising approach to gene prioritization.
Results: We present MendelVar, a comprehensive tool that integrates knowledge from four databases on Mendelian
disease genes with enrichment testing for a range of associated functional annotations such as Human Phenotype
Ontology, Disease Ontology and variants from ClinVar. This open web-based platform enables users to strengthen
the case for causal importance of phenotypically matched candidate genes at GWAS loci. We demonstrate the use
of MendelVar in post-GWAS gene annotation for type 1 diabetes, type 2 diabetes, blood lipids and atopic dermatitis.
Availability and implementation: MendelVar is freely available at https://mendelvar.mrcieu.ac.uk
Contact: maria.sobczyk@bristol.ac.uk
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
The last decade has delivered a bounty of genetic data due to advan-
ces in high-throughput DNA sequencing and genotyping. On the
one hand, this has led to dramatic advances in investigation of the
genetic basis of complex, polygenic disease and traits with 9407
studies featured in the GWAS Catalog as of October 2020 (Buniello
et al., 2019). However, the detection of a GWAS signal alone does
not identify the causal gene at a locus and so substantial bioinfor-
matics and experimental effort is still required to convert such find-
ings into useful biological insight. At the other end of the spectrum,
Mendelian monogenic disease research has benefitted tremendously
from recent sequencing methods, which helped to detect the causal
genes in >1000 Mendelian conditions (Bamshad et al., 2019). In
contrast to complex trait loci, large-effect sizes and typically mis-
sense consequences of Mendelian perturbations mean the causal
gene is more easily detected using statistical methods alone, resulting
in a direct link between phenotype and gene. In MendelVar, we util-
ize these direct links between phenotypes and genes from Mendelian
traits to aid in identifying causal genes and pathways implicated in
GWAS of complex traits.
MendelVar is a unique comprehensive tool linking the informa-
tion obtained about gene function in Mendelian disease research to
help inform candidate gene prioritization in GWAS. First, it makes
it easy to find associations of a given set of genomic intervals or sin-
gle nucleotide polymorphisms (SNPs) with Mendelian disease in a
range of databases. Second, it tests for enrichment of disease pheno-
type and gene ontology terms associated with detected Mendelian
disease. MendelVar is presented as a freely available and regularly
updated webserver accessible on: https://mendelvar.mrcieu.ac.uk/.
The number of genes with a known disruption resulting in a
Mendelian disorder currently totals 4229 genes in Mendelian
Inheritance In Man (OMIM) (October 2020). With 300 new
Mendelian phenotypes added to the database every year, there is a
large scope for an increase in numbers for genes associated with
Mendelian disease. Therefore, MendelVar will be regularly updated
with new findings on Mendelian disease genes.
Many common complex diseases (caused by hundreds of loci
with small effect) contain a small subcohort of individuals with
monogenic large-effect disruption in key genes driving complex dis-
ease—with examples including coronary artery disease, diabesity,
obesity and autism (Chong et al., 2015). Since small-effect muta-
tions in the affected genes circulate in the general at-risk population,
function of genes affected in the monogenic forms can inform us
about the main biological processes involved in complex disease
aetiology and aid therapeutic development.
Freund et al. (2018) have shown that gene sets with confirmed
phenotypically matching or related Mendelian lesions are 27 times
more likely to be enriched among all GWAS genes across 62 human
traits compared to phenotypically unrelated sets of Mendelian dis-
ease genes. Examples include enrichment of growth defect genes in
the height GWAS or immune dysregulation genes in a range of
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inflammatory conditions, such as inflammatory bowel disease. In
general, Mendelian disease genes show enrichment among genes
flanking the low P-value disease GWAS loci and their occurrence
positively correlates with association strength (Chong et al., 2015).
Widespread comorbidity has also been detected between Mendelian
disease and complex disease (Blair et al., 2013) including cancer
(Melamed et al., 2015), which can potentially be driven by plei-
otropy (Pividori et al., 2019). The established involvement of certain
Mendelian disease genes in complex traits has started to become uti-
lized in evaluating GWAS gene prioritization algorithms (Barbeira
et al., 2019; Guo et al., 2019) and indeed, in gene prioritization itself
(Schlosser et al., 2020). MendelVar aims to simplify this process of
integrating information about Mendelian disease to prioritize candi-
date causal genes at GWAS loci. It has been indicated that
Mendelian disease-linked genes make for more successful drug tar-
gets (King et al., 2019; Nelson et al., 2015) and so integration of
Mendelian disease data may be especially useful in prioritizing the
loci with Mendelian disease evidence for pharmaceutical
interventions.
MendelVar allows quick assessment of the likely impact of
Mendelian disease-related genes from specified genomic regions
(identified by GWAS or other means) on the user’s complex pheno-
type of interest. It lists the details of all the Mendelian disease genes
found in the input genomic intervals, extracted from OMIM and
similar databases, as well as the closest rare mutations mapped to
them available in ClinVar. INRICH is then used for calculating the
enrichment of Disease Ontology (DO) and Human Phenotype
Ontology (HPO) terms amongst the background of all Mendelian
disease-related genes, giving the researcher an overview of any pos-
sible shared phenotypic features of identified Mendelian genes with
the trait of interest, e.g. in terms of anatomy.
In this paper, we first describe the process of identification, filter-
ing and integration of Mendelian disease data sources. We compare
MendelVar with similar tools in terms of analytical features and the
breadth of data mined. Following that, we present different possible
MendelVar workflows and apply these to three example traits.
2 Materials and methods
Full details of how the MendelVar database was constructed is avail-
able in the Supplementary Material, but briefly:
Disease-gene relationships from OMIM, Deciphering
Developmental Disorders Study (DECIPHER), Orphanet and
Genomics England were extracted and integrated. Gene coordinates
were defined according to the canonical transcript reported in
APPRIS or GENCODE. In addition, variant-disease relationships
were also extracted from ClinVar to enable identification of variants
of interest in the regions under investigation. The disease genes were
mapped to a range of ontologies (described in the implementation)
to enable relevant phenotype searching within the results, and also




3.1.1 Integration of MendelVar data sources
The paramount reference for description of Mendelian disease and
their causal genes is the (Online) OMIM database (Amberger et al.,
2019). MendelVar uses all the confirmed gene-disease relationships
featured in OMIM and complements it with three more specialist
data sources for Mendelian disease: Orphanet (Rath et al., 2012) (a
database centred on rare, typically monogenic disease), expertly
curated gene panels used for diagnostics from Genomics England
PanelApp (Martin et al., 2019) and results from the on-going
Deciphering Developmental Disorders Study (DECIPHER)—whose
aim is to identify de novo microgenomic rearrangements responsible
for undiagnosed developmental delay disorders (Firth et al., 2009).
While OMIM is the established reference for mapping
Mendelian disease to genes, adding gene-disease associations from
DECIPHER, Orphanet and Genomics England panels allows discov-
ery of more genes compared to OMIM alone (Table 1). The 12 344
gene-disease relationships in MendelVar contain 4843 unique genes,
552 of them not assigned to any Mendelian disease in OMIM.
Integration of the four data sources resulted in 12 344 gene-disease
relationships, compared to 6471 present in OMIM alone. Although
there is some redundancy, across Orphanet, DECIPHER and
Genomics England, we found at least 1925 gene-disease associations
(either at an individual disease level or same phenotypic series level)
that were not in OMIM (i.e. counting only entries that have both
gene and disease OMIM ID assigned).
MendelVar includes short disease descriptions sourced from
OMIM, Orphanet, Uniprot (Breuza et al., 2016) and DO (Schriml
et al., 2019). Out of 12 344 gene-disease entries in the MendelVar
database, 9899 contain a disease description, amounting to 5329
unique disease descriptions.
In addition, MendelVar cross-references input genomic intervals
against ClinVar (Landrum et al., 2019) for pathogenic or likely
pathogenic variants implicated in Mendelian disease allowing identi-
fication of mostly genic variants and repeats in linkage-disequilib-
rium (LD) with region of interest. Due to small differences in
genome builds, 134 347 and 130 123 ClinVar variants are present
in the GRCh37 and GRCh38, respectively.
Following extraction of Mendelian disease-linked target genes
from the MendelVar database, MendelVar provides enrichment test-
ing of any specific phenotypic class associated with the disease in
question. This is done by first annotating the target genes with all
the ontology terms associated with all the Mendelian diseases caused
by any mutation in the gene. MendelVar provides easy enrichment
testing using human DO and HPO, their respective slim ontologies
and Freund et al. (2018)’s 20 Mendelian gene sets based around
broad phenotypic categories. The DO focuses on defining a hier-
archy of disease aetiology classes which include affected anatomical
entity and part of metabolism, amongst others. The main remit of
HPO (Köhler et al., 2019) is the classification of clinical symptoms
and abnormalities associated with disease.
In MendelVar, HPO terms were collected first from OMIM, and
then complemented with Orphanet, Decipher DDG2P and official
HPO annotations, which altogether contributed HPO terms to 423
diseases with no previous HPO terms in OMIM. Similarly, DO
terms were first mined from OMIM, followed by Orphanet and the
official DO annotation. The latter two sources provided DO annota-
tion to 579 diseases with no previous annotation in OMIM. Out of
12 344 gene-disease entries in the MendelVar database, 10 215
(6284 unique diseases) have at least one HPO term assigned and
6574 (3564 unique diseases) have a DO term assigned. In total, we
include 9209 distinct HPO and 4651 DO terms in the MendelVar
database. The mean number of all HPO terms and DO terms is
149.2 (20.3 independent leaf terms) and 10.5 (2 independent leaf
terms) per ontology-annotated gene, accordingly.
MendelVar also incorporates the Gene Ontology (Carbon et al.,
2019), Pathway Commons (Cerami et al., 2011), Reactome
(Fabregat et al., 2018) and ConsensusPathDb (Herwig et al., 2016)
allowing custom testing for enrichment of molecular and biochem-
ical gene pathways against the null background of all Mendelian dis-
ease genes in the human genome.
Table 1. Comparison of MendelVar with its Mendelian disease
source databases
OMIM Orphaa GEb DECIPHER MendelVar
Number of genes 4229 4202 3244 2198 4843
Number of diseases 5618 3817 4430 2873 7532
Number of gene-
disease associations
6471 7619 5019 3679 12 344
aOrphanet.
bGenomics England.
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3.1.2 User input for MendelVar webserver
The MendelVar webserver accepts a maximum input of 10 000 gen-
omic positions or intervals, with a maximum interval size of
20 Mbp.
MendelVar offers three general routes through the pipeline de-
pending on the type of user input. The user can either submit prede-
fined GRCh37 or GRCh38 genomic intervals based on their own
analysis pipeline (Fig. 1 right) or a list of single genomic positions
(e.g. GWAS lead SNPs) from which MendelVar will create the inter-
vals to be used. These intervals can be created in two ways. Either,
user-specified left and right flanks can be generated around the input
positions, up to a maximum of 10 Mbp in each direction (Fig. 1
left), or, flexible LD-based intervals can be created using the LDlink
LDproxy app (Machiela and Chanock, 2015), either through dbSNP
rsIDs or single positional coordinates (Fig. 1 centre) from GRCh37
(hg19) or GRCh38 (hg38) assemblies. Using an LD statistic of
choice: r2 or D0, LD is calculated within the 1 Mbp window centred
on the input SNP with LDlink. Boundaries around the input variant
are generated by finding the most distant upstream and downstream
variant meeting the specified minimum LD threshold (between 0
and 1) in the selected target 1000 Genomes population: CEU (Utah
residents of northern European descent), EUR (European), EAS
(East Asian), SAS (South Asian), AFR (African) or AMR (Ad-mixed
American). This generated interval can be extended to the nearest
recombination hotspot with a recombination rate >3 cM/Mb
(Myers et al., 2008) based on HapMap II. As LDlink accepts only
GRCh37 coordinates, we initially map user-submitted GRCh38
coordinates to GRCh37 coordinates with the UCSC liftOver tool
(Haeussler et al., 2019). Therefore, the last step in the case of user
input in GRCh38 coordinates is to convert the LDlink-createD.
GRCh37 intervals, optionally extended to the nearest recombin-
ation hotspot, back to GRCh38 coordinates using the UCSC
liftOver tool.
3.1.3 Identification of overlapping mendelian genes
Genes are defined as overlapping with the genomic intervals based
on coordinates of canonical APPRIS (Rodriguez et al., 2013) tran-
script isoforms if available or alternatively the longest transcript for
a given gene; the overlap step is performed with GIGGLE (Layer
et al., 2018).
Users can extend the gene region by up to 20 kbp in upstream or
downstream direction since most of the strong eQTLs (expression
quantitative trait loci) regulating gene expression are found in that
region (Veyrieras et al., 2008). It is not recommended to extend the
gene region too much, as this can result in more genes overlapping
each other and being collapsed by INRICH (Lee et al., 2012), which
will then result in a loss of power in the ‘gene’ INRICH mode (see
below).
3.1.4 Enrichment testing
Following identification of Mendelian disease-associated genes over-
lapping the input genomic intervals, MendelVar allows testing for
enrichment of terms associated with those genes relative to the back-
ground of all Mendelian disease-associated genes in the genome. Of
particular interest in GWAS for complex traits (and uniquely com-
pared to other tools), we allow simultaneous testing using HPO, DO
and Freund et al. (2018) gene sets. To give the user an overview of
general categories associated with both ontologies and boost statis-
tical power, MendelVar includes the official DO slim (24 terms) and
custom-generated HPO slim (25 direct descendants of the root term
‘Phenotypic abnormality’). In addition, general gene enrichment test-
ing is available with Gene Ontology and its slim version, and path-
way enrichment testing with ConsensusPathDB, PathwayCommons
and Reactome.
Enrichment testing in INRICH can be run in two modes:
‘gene’ and ‘interval’. In the ‘gene’ mode, the enrichment statistic
is calculated over the number of genes in all intervals overlapping
a given ontology term. In the ‘interval’ mode, the enrichment
statistic is calculated over the number of intervals with at least
one gene (regardless of gene number within interval) overlapping
a given ontology term. In general, ‘gene’ mode should result in
higher power to detect enrichment in the context of typical
MendelVar usage, if we expect multiple genes with related func-
tions to clusteR.
3.1.5 Mendelvar output
The average run time using 100 single variant positions, interval
generation with LDlink and enrichment testing using all ontologies
is 5 h due to resampling and bootstrapping steps in INRICH. Two
main results tables are produced, which detail the overlap of input
genomic intervals with Mendelian-disease causing genes and
Fig. 1. A flowchart demonstrating three possible user routes through MendelVar: (a)
left: MendelVar generates fixed genomic intervals using preset left and right flanks
against a user-submitted list of genomic positions; (b) centre: MendelVar generates
flexible genomic intervals using LD pattern in the region around each user-submit-
ted position/variant rsID; (c) right: MendelVar accepts user-submitted genomic
intervals. The genomic intervals generated or obtained from user are subsequently
bisected with coordinates for genes and variants known to cause Mendelian disease.
Ontology terms associated with Mendelian disease in HPO, DO are propagated to
causal genes and are tested for enrichment among target genes in input genomic
intervals. MendelVar also provides an option for enrichment testing with Gene
Ontology and biological pathway databases
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variants, respectively (see example Supplementary Tables S1 and S2
and abbreviated in Table 2, full results for example traits in
Datasets S1–S7). Results of enrichment testing using each ontology
are provided in individual tables and are summarized in a set of fig-
ures (see example Figs 2 and 3, full results for example traits in
Datasets S1–S7).
3.2 Comparison with related tools
We compared MendelVar to seven most closely matched applica-
tions, which also facilitate the use of Mendelian disease data in
human genetics research (Supplementary Table S3). These tools
show differences in accepted inputs, datasets included and overall
philosophy and goals of the analysis. Broadly scoped tools such
as FUMA (Watanabe et al., 2017) provide an excellent starting
point for GWAS annotation by providing access to rich compen-
dium of resources and analyses, such as gene expression, chroma-
tin interactions and eQTLs. However, by the virtue of being so
wide-ranging, they provide only a limited overview of the GWAS
link to Mendelian disease and their phenotypes. Packages such as
VarfromPDB (Cao et al., 2017), while integrating a selection of
the datasets present in MendelVar, are built on a reverse premise
and mine for variants and genes associated with a phenotype/dis-
ease input by the user. Tools such as MARRVEL (Wang et al.,
2017), FUMA (Watanabe et al., 2017) and DisGeNET (Pi~nero
et al., 2017) annotate input genes with matching Mendelian dis-
orders from only a subset of databases integrated in MendelVar.
Whilst the Open Targets Platform (Carvalho-Silva et al., 2019)
does collate Mendelian gene evidence for linking genes to disease,
this is not a feature of its variant-based search. None of these
four tools includes annotation with the full set of human DO
and Phenotype Ontology terms or features enrichment testing of
these terms.
Another comparison group consists of tools such as
clusterProfiler (Yu et al., 2012), DAVID (Huang et al., 2009) and
Enrichr (Kuleshov et al., 2016). These are popular gene set enrich-
ment packages widely employed in interpreting long gene lists result-
ing from high-throughput genomics and transcriptomics
experiments. Despite a large number of compatible ontologies, they
never feature more than one of the key ontologies (DO, HPO) avail-
able in MendelVar and do not carry out the background gene selec-
tion sampling taking into account genomic confounders such as SNP
density and gene size/density which are required for appropriate
GWAS analysis. Simulations have shown that ignoring these con-
founders in enrichment analysis in GWAS studies and assuming in-
dependence can result in up to 100% type I error in some cases,
whilst it never exceeds the nominal 5% in INRICH (Lee et al.,
2012). Finally, in terms of flexibility of user input, other than
Enrichr, MendelVar is the only enrichment tool to accept genomic
coordinates.
We expect that MendelVar users may also utilize other tools in
order to triangulate evidence across different data sources, but
MendelVar provides the most comprehensive analysis of the rele-
vant Mendelian disease gene data and aims to do so in a flexible and
user-friendly way.
Table 2. Output from the MendelVar main results table (select columns out of 20)














Lissencephaly 9 with complex brainstem mal-
formation; defects in neuronal migration
and axon guidance; posterior-predominant
lissencephaly broad flat pons and medulla-
midline crossing defects syndrome
Insulin resistance, susceptibility to; leanness,
inherited; lipodystrophy, familial partial,
type 3; carotid intimal medial thickness 1;
thyroid carcinoma, Hurthle cell; Giant cell
glioblastoma; Gliosarcoma
Insulin resistance, susceptibility to neurodeve-
lopmental disorder with dysmorphic facies
and distal skeletal anomalies; neurodeve-
lopmental disorder with dysmorphic facies









Note: An abbreviated version of the full disease-based results table (Dataset S2) from the T2D MendelVar analysis.*
We include the first locus in the genome (as an unselected example) and then the three loci for which Grotz et al. (2017) have reported causal genes. Sometimes
the ontological connection with the trait of interest is apparent, whilst in other cases the genes returned may be false positives. The enrichment results can help to
distinguish these.
Fig. 2. Top enrichment results for HPO terms among Mendelian disease genes
located within LD-based intervals around lead SNPs in Onengut-Gumuscu et al.
(2015) T1D GWAS. An example of a summary figure produced by MendelVar pipe-
line depicts top 50 most significant terms in the ontology (y axis), sorted first by em-
pirical P-value followed by the number of genes overlapping the ontology term in
the tested genomic intervals in case of ties (also shown independently on the x axis).
The size of each data point represents ratio of gene overlap, i.e. number of genes
found in the tested genomic intervals divided by all Mendelian genes annotated with
that ontology term available in the genome. Each data point is coloured according
to empirical P-value for enrichment significance
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3.3 MendelVar use cases
3.3.1 Type 1 and type 2 diabetes GWAS
In order to evaluate MendelVar’s usefulness in polygenic traits with
varying genetic architecture, we applied it to analysis of type 1 dia-
betes (T1D) and type 2 diabetes (T2D) GWAS. These two common
diseases can be contrasted as, despite a similar clinical endpoint
(hyperglycaemia), they differ in general disease mechanism and gen-
etic architecture (Timpson et al., 2018). Susceptibility to T1D has
been shown to depend on lower-frequency common variants, many
with large-effect size, whereas high-frequency common variants of
small-effect size contribute to the overall risk of T2D.
MendelVar was used to generate LD-based intervals (r2>0.8 in
Europeans) around lead SNPs downloaded from the GWAS Catalog
(Milano et al., 2017). Genome-wide significantly enriched terms in
DO and HPO matched known disease biology. In the case of T1D
(Onengut-Gumuscu et al., 2015), we found enrichment of terms
(Figs 2 and S1, Dataset S1): abnormality of digestive system morph-
ology, glucose metabolism disease, terms related to T1D’s auto-
immune root cause (autoimmune disease, primary
immunodeficiency disease) and secondary symptoms of the disease
such as vascular problems (vasculitis) (Schram et al., 2003), diabetic
eye disease (inflammatory abnormality of the eye, anterior uveitis)
(Watanabe et al., 2019). T2D (Xue et al., 2018) results showed en-
richment of terms (Figs 3 and S2, Dataset S2) associated with insulin
and glucose imbalance (insulin resistance, glucose metabolism dis-
ease, impaired glucose tolerance, glycosuria, polydipsia) and pan-
creas dysfunction (abnormality of endocrine pancreas physiology,
pancreatic hypoplasia, abnormality of the pancreatic islet cells). In
both T1D and T2D, we found enrichment of monogenic forms of
diabetes, as expected (Yang and Chan, 2016)—2 genes in T1D
(RASGRP1, INS) and 8 in T2D (HNF1B, GCK, WFS1, KCNJ11,
ABCC8, HNF1A, PPARG, SLC2A2). We also found three
Mendelian disease genes (Table 2) which were listed as ‘solved’ T2D
loci with experimental evidence in a recent review (Grotz et al.,
2017). However, in one example, MendelVar highlights a known
causal gene (ZMIZ1), but the Mendelian disease is not phenotypic-
ally aligned with the GWAS trait. Comparison of a number of
Mendelian disease genes annotated with the enriched DO and HPO
terms revealed A higher relative rate in T1D—32 genes assigned to
25 loci (out of 51 GWAS loci, 49%) versus 38 genes assigned to 29
loci (out of 150 GWAS loci, 19.3%) in T2D. The rate disparity
decreased when considering any overlapping Mendelian disease
genes: 47 genes were detected at 31 loci in T1D (60.8%) compared
to 109 genes at 68 loci in T2D (45.3%).
3.3.2 LDL And HDL plasma concentration GWAS
Since there are likely to be ancestral biases in Mendelian gene data-
bases similar to those found in populations sampled in GWAS (Mills
and Rahal, 2020), we wanted to investigate whether use of
MendelVar on GWAS of the same traits in samples with different
ancestries (but with comparable sample size) produced similar
results in terms of genes identified and enrichment of annotated
terms. In addition, low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) GWAS provide further examples of quantitative
traits with a broad spectrum of effect sizes (Timpson et al., 2018).
Having downloaded the lead SNPs from the GWAS Catalog for
each trait in European (LDL n¼85 491, HDL n¼89 614)
(Teslovich et al., 2010) and East Asian (LDL n¼72 866, HDL
n¼70 657) (Kanai et al., 2018) GWAS, we followed the MendelVar
route depicted in Figure 1b of generating LD-based intervals
(r2>0.8) using a reference from European or East Asian 1000
Genomes population, respectively.
In general, we found genome-wide significant enrichment of
HPO and DO terms to be shared across ancestries for LDL and
HDL. A third of GWAS lipoprotein loci have been previously linked
to genes directly involved in plasma lipoprotein metabolism, muta-
tions in which frequently cause familial dyslipidemias (Dron and
Hegele, 2016). Unsurprisingly, for LDL, we found enrichment of
genes associated with terms such as: familial hyperlipidaemias,
increased/abnormal LDL-cholesterol concentration, xanthelasma as
well as terms related to known cardiovascular consequences of
unbalanced LDL concentration (Wadhera et al., 2016): arterial cal-
cification, myocardial steatosis, cerebral artery atherosclerosis, cor-
onary artery aneurysm (Datasets S3 and S4). Similar terms but
correctly identifying decreased/abnormal HDL cholesterol concen-
tration were found to be enriched across HDL GWAS (Datasets S5
and S6).
As direct comparison between GWAS would be biased by the
number of loci detected in each study and the clumping strategy
used to define independent loci, we carried out repeated resampling
of SNPs from independent loci to make the rate of MendelVar anno-
tation more comparable (Table S4).
On average, 64.5% of loci in European LDL GWAS and 47%
loci in East Asian GWAS were linked to any Mendelian disease.
However, in HDL GWAS, the proportions were reversed across
populations: 45.2% in European with any Mendelian disease anno-
tation compared to 55.2% in East Asian. We found the same direc-
tion of difference when focussed only on diseases associated with
HPO and DO terms enriched within either of the two populations.
3.3.3 Atopic dermatitis GWAS
Lastly, we believe that MendelVar could potentially be useful in
investigating subsignificant GWAS loci, to determine which loci (of
all those that reach a suggestive P-value threshold) also have consist-
ent independent evidence implicating loci gene with the disease. As
an example, we investigated 157 loci with P-value of between
>5108 and <1104 in the EAGLE atopic dermatitis (eczema)
GWAS (Paternoster et al., 2015), and for each signal we defined a
strict LD-based interval thresholded at r2>0.6 (Dataset S7). Among
72 Mendelian disease genes overlapping the intervals, 34 are associ-
ated with the general abnormality of the skin HPO term and 6 with
the more specific top hit abnormality of epidermal morphology. On
further investigation, one of these had evidence of eQTL colocaliza-
tion (Giambartolomei et al., 2014) in the skin: the 18q21.33 locus
represented by the lead SNP rs35112771 (intronic) with a P-value of
2.1105. The region showed convincing evidence of colocalization
(83.5%) with SERPINB7 eQTLs only in the sun-unexposed skin tis-
sue type of GTEx study ver. 7 (Ardlie et al., 2015). Crucially,
SERPINB7’s expression is elevated in the epidermis, and nonsense
mutations in the gene cause Nagashima-Type Palmoplantar
Keratosis, characterized by well-demarcated diffuse hyperkeratosis
with redness on palms and feet (Kubo et al., 2013). This phenotype
is widely found in a range of eczematous conditions (Agner et al.,
2015; Lee et al., 2009; Thestrup-Pedersen et al., 2001) and would
suggest that common mutations affecting SERPINB7 expression
Fig. 3. Top enrichment results for HPO terms among Mendelian disease genes
located LD-based intervals around lead SNPs in Xue et al. (2018) T2D GWAS. in a
single locus. However, one consequence in the context of GWAS is that this enrich-
ment value will be biased by the same GWAS signal counted multiple times
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could partially explain the missing heritability in atopic dermatitis
GWAS.
4 Discussion
MendelVar is a unique webserver/pipeline dedicated to automatic
assessment of the genetic and phenotypic link between Mendelian
disease genes and hits at complex trait GWAS loci. It maps
Mendelian disease to relevant variants and disease phenotypes as
well as descriptions from a comprehensive sampling of public data-
bases reporting Mendelian gene-disease associations. MendelVar’s
rich database contains 4843 unique genes, 12 344 gene-disease rela-
tionships—80.2% with a disease description, 82.8% with HPO an-
notation, 53.2% with DO annotation; all complemented by
130 000 ClinVar rare variants. The Mendelian disease phenotypes
and other gene ontology terms are then tested for enrichment in a
GWAS-suitable framework. These features are integrated into a
streamlined process beginning with input of genomic coordinates or
variant rsIDs by the user. MendelVar delegates to the user a great
deal of flexibility regarding workflow: allowing definition of a crude
fixed interval around input genomic positions (GRCh38/hg38 or
GRCh37/hg19), mapping positions or rsIDs to flexible LD-based
regions or input of custom genomic intervals derived using inde-
pendent methods. Our goal was to integrate all publicly available
data sources mapping Mendelian disease to genes; hence, our inclu-
sion of Orphanet, Genomics England PanelApp and DECIPHER to
supplement the chief authority on Mendelian disease—OMIM. This
strategy proved beneficial as MendelVar includes 629 novel genes
and at least 1925 new gene-disease associations in addition to those
provided by OMIM. For instance, CREB3L3 and CDX1 are not
assigned any disorders on OMIM but are on the ‘severe hypertrigly-
ceridaemia’ panel and ‘nonsyndromic familial congenital anorectal
malformations’ panel, respectively, in the Genomics England
PanelApp.
The absence of given gene-disease connections in OMIM may re-
sult from a delay due to its reliance on literature rather than clinical
data, but also OMIM’s stricter requirements for inclusion and re-
dundancy. Some links in the non-OMIM sources and supported by
the older literature have been deemed not strong enough to deserve
a separate entry in OMIM, e.g. the link between KCNJ8 and Cantú
syndrome (Cooper et al., 2014) reported in DECIPHER or a link be-
tween PLXND1 and Moebius syndrome in Orphanet (Tomas-Roca
et al., 2015). Each gene-disease entry in the MendelVar results table
lists all the data sources supporting the causal link, allowing case-
by-case assessment by the user.
Some information is likely to be partially or wholly redundant
due to different criteria for assignment to related conditions. For in-
stance, DECIPHER reports SATB2 to be linked to simply ‘cleft pal-
ate’, whereas in OMIM the gene is mapped to Glass syndrome, for
which one of the hallmarks is cleft palate. Similarly, Orphanet can
present alternative assignment of genes to rare diseases relative to
OMIM. For instance, TRDN is assigned to Romano–Ward syn-
drome on Orphanet and ‘Ventricular tachycardia, catecholaminergic
polymorphic, 5, with or without muscle weakness’ on OMIM, des-
pite the fact that Romano–Ward syndrome is also present in the
OMIM database; both diseases are forms of cardiac arrhythmias.
Care needs to be taken when interpreting ontology enrichment
results and enriched terms need to be cross-referenced with target
trait phenotypes due to false positives stemming from horizontal
pleiotropy. For instance, extensive overlap in the genetic aetiology
of T1D with rheumatoid arthritis (RA) has been documented
(Onengut-Gumuscu et al., 2015). In line with this, our MendelVar
analysis of the T1D GWAS finds significant enrichment of DO and
HPO terms associated with RA such as: rheumatoid arthritis, auto-
immune disease of musculoskeletal system. Similarly, while abnor-
mality in the level of circulating neutrophils and platelets has been
detected in T1D (Valle et al., 2013), more specific blood cell type
abnormalities were, likely incorrectly, enriched in the MendelVar
analysis. In this scenario, while the enriched terms may be false, the
underlying shared genetic component could informatively point to a
shared causal gene, such as PTPN22 in T1D and RA (Bottini et al.,
2006).
Integration of Mendelian disease genetics into prioritization of
genes at GWAS loci may have a positive impact on drug discovery
pipelines. Studies have shown that the probability of progression
along a drug development pipeline is greater for target-indication
pairs with genetic evidence, and that OMIM genetic evidence has a
greater effect on approval than GWAS evidence, e.g. phase I to ap-
proval progression risk ratio for GWAS¼1.4 (95% CI 1.1–1.7),
OMIM¼2.7 (95% CI 2.4–3.1) (King et al., 2019; Nelson et al.,
2015). Thorough analysis has demonstrated that this difference is
unlikely to be due to a statistical artefact or reverse causation,
whereby the OMIM entry is influenced by the knowledge of success-
ful drug trials (King et al., 2019). However, the higher probability
of progression along drug development pipelines for OMIM genes
may be influenced by Mendelian conditions having larger genetic
risk factor effects than common GWAS traits (rather than just
increased likelihood of identifying the true causal gene) and so it
remains to be seen whether the use of Mendelian genetic data to link
GWAS hits to causal genes will result in the same positive impact on
drug approval. Despite this, genes prioritized by MendelVar may
make for attractive targets for pharmaceutical companies as they
may prove to be effective for more than one condition (i.e. both the
common GWAS condition and the rarer Mendelian condition).
Examples of successful drugs targeting Mendelian disease genes
which are used to treat common conditions include PCSK9 antibod-
ies and orexin antagonists. Monogenic forms of hypercholesterol-
aemia have implicated key genes in the LDL-cholesterol transport
pathway, including PCSK9, with PCSK9 monoclonal antibodies
evolocumab and alirocumab now indicated for treatment of com-
mon hyperlipidaemia. Dominant loss-of-function mutations in the
orexin gene can cause narcolepsy; an orexin receptor antagonist
drug (suvorexant) has proven effective for treating insomnia
(Coleman et al., 2017).
In this paper, we demonstrate the application of MendelVar to a
selection of traits with different genetic architectures and ancestries
of the population sample. Enrichment testing results highlight
Mendelian disease genes with plausible links to tested traits. Based
on the limited evidence of T1D versus T2D comparison, traits with
lower-frequency and higher-effect size variants such as T1D may ob-
tain better annotation from MendelVar, as previously shown
(Freund et al., 2018). Nevertheless, close to 1 in five loci in the T2D
GWAS were assigned at least one candidate gene with relevant
enriched disease symptoms, which remains highly informative.
Standardized comparison of LDL and HDL GWAS across East
Asian and European populations showed no consistent bias towards
improved MendelVar annotation in either group. In fact, the major-
ity of other trans-ancestry comparisons among adequately sized
GWAS replicate common variant associations of origin predating
human population divergence and tag the same loci with consistent
direction and size of effect (Gurdasani et al., 2019; Marigorta and
Navarro, 2013; Shi et al., 2020). Overwhelming concordance has
been confirmed between more recent blood lipid GWAS with high
sample size in Europeans and trans-ancestry analysis of smaller sam-
ple size (Hu et al., 2020).
The MendelVar approach to gene prioritization is limited by the
number of genes with known Mendelian phenotypes (4843). As an
example, we have examined the likely causal genes highlighted for
T2D (Grotz et al., 2017) and MendelVar identifies PPARG,
SLC30A8, ZMIZ1, but not KLF14, which currently lacks a
Mendelian disease assignment. The method used to define input
intervals will also affect MendelVar’s findings. Our AD example
using LD-defined intervals (r2>0.6) does not return the known
causal gene FLG (Paternoster et al., 2015) at its top locus but its
paralog FLG2 instead due to FLG placement outside the generated
interval. Prior evidence shows that we might expect only about 83%
of GWAS lead variants to be in tight LD (r2>0.8) with the causal
gene, estimated (188/227) from known causal genes behind metab-
olite QTLs (Stacey et al., 2019), and so we have to expect that any
method using LD to define a candidate gene list will not work for all
loci. When defining the region purely by genomic distance, at 445
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gold standard curated GWAS loci (Mountjoy et al., 2020) 90.9% of
causal genes are within 100 kbp and 99.9% are within 1 Mbp, re-
spectively, of the lead SNP and so MendelVar’s maximum interval
size of 610 Mbp will encompass the vast majority of causal genes.
As shown by examples of identification of candidate genes and
enriched disease phenotypes/classes in T1D, T2D, LDL, HDL and
atopic dermatitis GWAS, we envisage that MendelVar will be espe-
cially useful in the annotation and interpretation of GWAS results,
but the flexibility of the user input enables other applications, such
as in EWAS (epigenome-wide association studies). Ours and previ-
ous analyses (Freund et al., 2018) underscore that MendelVar can
be relied on to highlight enrichment of relevant biological processes
implicated in investigated trait/disease. However, the degree of en-
richment observed can vary depending on the relative contribution
of Mendelian disease genes to a given trait.
MendelVar’s structured and comprehensive output allows inclu-
sion into GWAS interpretation pipelines to complement other meth-
ods such as: Bayesian variant fine-mapping, variant pathogenicity
prediction, molecular QTL mapping and colocalization, chromo-
some confirmation capture for identifying regulatory loops. As an
example, we present SERPINB7 as a new putative candidate gene in
atopic dermatitis GWAS due to not only a phenotypic match be-
tween its target Mendelian disease and eczema but also due to coloc-
alization evidence in the skin.
In summary, MendelVar provides a useful complementary method
aiding candidate gene prioritization in GWAS of traits with various
genetic architectures. MendelVar highlights disease processes, organ
abnormalities and symptoms enriched among Mendelian disease
genes which are likely dysregulated in phenotypically related complex
traits.
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Data availability
MendelVar webserver is publicly available on https://mendelvar.
mrcieu.ac.uk.
Detailed MendelVar tutorial can be found on https://bitly.com/
MendelVar or https://www.notion.so/mendelvar/MendelVar-tutor
ial-ab91d2a6acb846f2b9f2978fcd942dd5.
Code to reproduce MendelVar pipeline: https://github.com/
MRCIEU/mendelvar_standalone.
Dataset S1. MendelVar annotation results for Onengut-Gumuscu
et al. (2015) type 1 diabetes GWAS. https://doi.org/10.6084/m9.fig
share.13154465.
Dataset S2. MendelVar annotation results for Xue et al. (2018) type 2
diabetes GWAS. https://doi.org/10.6084/m9.figshare.13154480.
Dataset S3. MendelVar annotation results for Teslovich et al. (2010)
LDL GWAS. https://doi.org/10.6084/m9.figshare.13154567.
Dataset S4. MendelVar annotation results for Kanai et al. (2018)
LDL GWAS. https://doi.org/10.6084/m9.figshare.13154525.
Dataset S5. MendelVar annotation results for Teslovich et al. (2010)
HDL GWAS. https://doi.org/10.6084/m9.figshare.13154561.
Dataset S6. MendelVar annotation results for Kanai et al. (2018)
HDL GWAS. https://doi.org/10.6084/m9.figshare.13154504.
Dataset S7. MendelVar annotation results for (sub)-significant loci
in Paternoster et al. (2015) atopic dermatitis GWAS. https://doi.org/
10.6084/m9.figshare.12174864.
NB. Datasets S1–S7 contain the following standard MendelVar out-
put files:
• mendelvar.log: log file with MendelVar run parameters.
• input_file.bed: input submitted by user.
• disease_overlap.txt: overlap of user test intervals with
Mendelian-disease causing genes.
• variant_overlap.txt: overlap of user test intervals with
Mendelian-disease causing variants.
For each ontology tested for enrichment (DO, DO slim, HPO,
HPO slim, Freund et al. (2018), GO, GO slim, Pathway Commons,
Reactome, ConsensusPathDb), MendelVar provides:
• *.out.inrich.parsed: file with processed INRICH results.
• *.out.inrich: file with raw INRICH results.
• *.pdf and *.png: summary enrichment figure.
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